Major improvement in thyroid cancer survival of elderly patients in the Nordic countries.
1/5 보강
[OBJECTIVES] We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.
APA
Zitrický F, Koskinen A, et al. (2024). Major improvement in thyroid cancer survival of elderly patients in the Nordic countries.. European journal of endocrinology, 190(3), K32-K36. https://doi.org/10.1093/ejendo/lvae015
MLA
Zitrický F, et al.. "Major improvement in thyroid cancer survival of elderly patients in the Nordic countries.." European journal of endocrinology, vol. 190, no. 3, 2024, pp. K32-K36.
PMID
38436478
Abstract
[OBJECTIVES] We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.
[DESIGN] Population-based survival study.
[METHODS] Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.
[RESULTS] In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.
[CONCLUSIONS] Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.
[DESIGN] Population-based survival study.
[METHODS] Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.
[RESULTS] In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.
[CONCLUSIONS] Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.
MeSH Terms
Male; Humans; Female; Aged; Survival Rate; Risk Factors; Scandinavian and Nordic Countries; Finland; Norway; Sweden; Thyroid Neoplasms; Denmark; Incidence; Registries; Age Distribution